Home/News Feed/Recursion Pharmaceuticals' drug REC-4881 advances to FDA-agreed Phase 3 trials, boosting stock by 6%. Recursion Pharmaceuticals announced that the FDA has agreed to the design for Phase 3 trials of its drug REC-4881, an oral MEK1/2 inhibitor for treating familial adenomatous polyposis (FAP). This regulatory progress highlights the value of Recursion's AI-powered drug development platform, which virtually pre-tests drug molecules before clinical trials. While FAP is a rare condition, the advancement of REC-4881 is a significant milestone for the company and its technology, with Phase 3 trials expected to start in late 2027. The stock rose about 6% following the news, though such volatility is typical given recent price swings.
Recursion Pharmaceuticals (RXRX) shares gained 6.99% to USD 2.91 as of Nov 19, 2026 00:21 WIB on Pluang, moving closer to its 52-week low of USD 2.72 but still well below its 52-week high of USD 4.96. Despite the recent positive news, the stock remains volatile with a high sell order activity at 87%, reflecting cautious investor sentiment. The typical hold time on Pluang is 23 days, indicating relatively short-term trading interest in this health sector stock.